Skip to main content

Advertisement

SpringerLink
Log in

Intravitreal injection of bevacizumab and triamcinolone acetonide at the end of vitrectomy for diabetic vitreous hemorrhage: a comparative study

  • Retinal Disorders
  • Published:
Graefe's Archive for Clinical and Experimental Ophthalmology Aims and scope Submit manuscript

Abstract

Background

To study the clinical outcome and complications of intravitreal bevacizumab (IVB) versus triamcinolone acetonide (IVT) injections at the end of vitrectomy in patients with diabetic vitreous hemorrhage.

Methods

This is a retrospective comparative case study comprised of 156 eyes from 139 consecutive patients who underwent pars plana vitrectomy for diabetic vitreous hemorrhage (VH) with or without tractional retinal detachment (TRD). IVB (1.25 mg/0.05 ml) injection was done for 66 eyes (60 patients) and IVT (4 mg/0.1 ml) injection for 33 eyes (31 patients) at the end of vitrectomy, and no injection was done for 57 eyes (48 patients). Main outcome measures were best-corrected visual acuity (BCVA), intraocular pressure (IOP), and incidence of postoperative VH and reoperation with at least 12 months of follow-up.

Results

Early postoperative VH within 1 month postoperatively occurred in eight eyes (12.1%) from the IVB group, three eyes (9.1%) from the IVT group, and 21 eyes (36.8%) from the control group. The rate of early postoperative VH was significantly lower in the IVB and IVT group than the control group (p = 0.002 and 0.006, respectively). Late postoperative VH after 1 month postoperatively occurred in 11 eyes (16.7%) from the IVB group, three eyes (9.1%) from the IVT group, and 12 eyes (21.1%) from the control group. There was no difference between the three groups (P = 0.341). BCVA of the IVB, IVT, and control group at postoperative months 1, 3, 6, 9, and 12 significantly improved from the preoperative BCVA (p < 0.01, respectively). There was no difference for BCVA between the three groups at each follow-up period (p > 0.05). In only the IVT group, IOP at postoperative day 1 was higher than IOP preoperatively (p = 0.002). There was no significant difference in the rate of reoperation between the three groups (p = 0.275).

Conclusion

IVB and IVT injection at the end of diabetic vitrectomy is a useful adjunctive therapy for reducing early postoperative VH compared to the control group. IVB injection does not have a risk of a temporary rise of IOP, which the IVT group has.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Novak MA, Rice TA, Michels RG, Auer C (1984) Vitreous hemorrhage after vitrectomy for diabetic retinopathy. Ophthalmology 91:1485–1489

    CAS  PubMed  Google Scholar 

  2. Schachat AP, Oyakawa RT, Michels RG, Rice TA (1983) Complications of vitreous surgery for diabetic retinopathy. II. Postoperative complications. Ophthalmology 90:522–530

    CAS  PubMed  Google Scholar 

  3. Tolentino FI, Cajita VN, Gancayco T, Skates S (1989) Vitreous hemorrhage after closed vitrectomy for proliferative diabetic retinopathy. Ophthalmology 96:1495–1500

    CAS  PubMed  Google Scholar 

  4. Hershberger VS, Augsburger JJ, Hutchins RK, Raymond LA, Krug S (2004) Fibrovascular ingrowth at sclerotomy sites in vitrectomized diabetic eyes with recurrent vitreous hemorrhage: ultrasound biomicroscopy findings. Ophthalmology 111:1215–1221

    Article  PubMed  Google Scholar 

  5. de Bustros S, Glaser BM, Michels RG, Auer C (1985) Effect of epsilon-aminocaproic acid on postvitrectomy hemorrhage. Arch Ophthalmol 103:219–221

    PubMed  Google Scholar 

  6. Koutsandrea CN, Apostolopoulos MN, Chatzoulis DZ, Parikakis EA, Theodossiadis GP (2001) Hemostatic effects of SF6 after diabetic vitrectomy for vitreous hemorrhage. Acta Ophthalmol Scand 79:34–38

    Article  CAS  PubMed  Google Scholar 

  7. Hood PP, Cotter TP, Costello JF, Sampson AP (1999) Effect of intravenous corticosteroid on ex vivo leukotriene generation by blood leucocytes of normal and asthmatic patients. Thorax 54:1075–1082

    Article  CAS  PubMed  Google Scholar 

  8. Ozaki NK, Beharry KD, Nishihara KC, Akmal Y, Ang JG, Sheikh R, Modanlou HD (2002) Regulation of retinal vascular endothelial growth factor and receptors in rabbits exposed to hyperoxia. Invest Ophthalmol Vis Sci 43:1546–1557

    PubMed  Google Scholar 

  9. Wilson CA, Berkowitz BA, Sato Y, Ando N, Handa JT, De Juan E Jr (1992) Treatment with intravitreal steroid reduces blood-retinal barrier breakdown due to retinal photocoagulation. Arch Ophthalmol 110:1155–1159

    CAS  PubMed  Google Scholar 

  10. Faghihi H, Taheri A, Farahvash MS, Esfahani MR, Rajabi MT (2008) Intravitreal triamcinolone acetonide injection at the end of vitrectomy for diabetic vitreous hemorrhage: a randomized, clinical trial. Retina 28:1241–1246

    Article  PubMed  Google Scholar 

  11. Lee SY, Lee HG, Chung HW, Yoon YH, Kim JG (2007) Efficacy of intravitreal triamcinolone acetonide for eyes with postvitrectomy diabetic vitreous hemorrhage. Korean J Ophthalmol 21:208–212

    Article  PubMed  Google Scholar 

  12. Jonas JB, Kreissig I, Degenring R (2005) Intravitreal triamcinolone acetonide for treatment of intraocular proliferative, exudative, and neovascular diseases. Prog Retin Eye Res 24:587–611

    Article  CAS  PubMed  Google Scholar 

  13. Arevalo JF, Fromow-Guerra J, Quiroz-Mercado H, Sanchez JG, Wu L, Maia M, Berrocal MH, Solis-Vivanco A, Farah ME (2007) Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: results from the pan-American collaborative retina study group at 6-month follow-up. Ophthalmology 114:743–750

    Article  PubMed  Google Scholar 

  14. Haritoglou C, Kook D, Neubauer A, Wolf A, Priglinger S, Strauss R, Gandorfer A, Ulbig M, Kampik A (2006) Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina 26:999–1005

    Article  PubMed  Google Scholar 

  15. Jorge R, Costa RA, Calucci D, Cintra LP, Scott IU (2006) Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study). Retina 26:1006–1013

    Article  PubMed  Google Scholar 

  16. Oshima Y, Sakaguchi H, Gomi F, Tano Y (2006) Regression of iris neovascularization after intravitreal injection of bevacizumab in patients with proliferative diabetic retinopathy. Am J Ophthalmol 142:155–158

    Article  CAS  PubMed  Google Scholar 

  17. da RLD, Ribeiro JA, Costa RA, Barbosa JC, Scott IU, de Figueiredo-Pontes LL, Jorge R (2009) Intraoperative bleeding during vitrectomy for diabetic tractional retinal detachment with versus without preoperative intravitreal bevacizumab (IBeTra study). Br J Ophthalmol 93:688–691

    Article  Google Scholar 

  18. Oshima Y, Shima C, Wakabayashi T, Kusaka S, Shiraga F, Ohji M, Tano Y (2009) Microincision vitrectomy surgery and intravitreal bevacizumab as a surgical adjunct to treat diabetic traction retinal detachment. Ophthalmology 116:927–938

    Article  PubMed  Google Scholar 

  19. Rizzo S, Genovesi-Ebert F, Di Bartolo E, Vento A, Miniaci S, Williams G (2008) Injection of intravitreal bevacizumab (Avastin) as a preoperative adjunct before vitrectomy surgery in the treatment of severe proliferative diabetic retinopathy (PDR). Graefes Arch Clin Exp Ophthalmol 246:837–842

    Article  CAS  PubMed  Google Scholar 

  20. Yeoh J, Williams C, Allen P, Buttery R, Chiu D, Clark B, Essex R, McCombe M, Qureshi S, Campbell WG (2008) Avastin as an adjunct to vitrectomy in the management of severe proliferative diabetic retinopathy: a prospective case series. Clin Experiment Ophthalmol 36:449–454

    PubMed  Google Scholar 

  21. Yeung L, Liu L, Wu WC, Kuo YH, Chao AN, Chen KJ, Yang KJ, Chen TL, Lai CC (2009) Reducing the incidence of early postoperative vitreous haemorrhage by preoperative intravitreal bevacizumab in vitrectomy for diabetic tractional retinal detachment. Acta Ophthalmol

  22. Arevalo JF, Maia M, Flynn HW Jr, Saravia M, Avery RL, Wu L, Eid Farah M, Pieramici DJ, Berrocal MH, Sanchez JG (2008) Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy. Br J Ophthalmol 92:213–216

    Article  CAS  PubMed  Google Scholar 

  23. Holladay JT (1997) Proper method for calculating average visual acuity. J Refract Surg 13:388–391

    CAS  PubMed  Google Scholar 

  24. Hogan MJ, Kimura SJ, Thygeson P (1959) Signs and symptoms of uveitis. I. Anterior uveitis. Am J Ophthalmol 47:155–170

    CAS  PubMed  Google Scholar 

  25. Avery RL, Pearlman J, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ, Wendel R, Patel A (2006) Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 113:1695–1705

    Article  PubMed  Google Scholar 

  26. Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ (2006) Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 113:363–372

    Article  PubMed  Google Scholar 

  27. Chen E, Park CH (2006) Use of intravitreal bevacizumab as a preoperative adjunct for tractional retinal detachment repair in severe proliferative diabetic retinopathy. Retina 26:699–700

    Article  PubMed  Google Scholar 

  28. Ishikawa K, Honda S, Tsukahara Y, Negi A (2009) Preferable use of intravitreal bevacizumab as a pretreatment of vitrectomy for severe proliferative diabetic retinopathy. Eye 23:108–111

    Article  CAS  PubMed  Google Scholar 

  29. Lo WR, Kim SJ, Aaberg TM Sr, Bergstrom C, Srivastava SK, Yan J, Martin DF, Hubbard GB 3rd (2009) Visual outcomes and incidence of recurrent vitreous hemorrhage after vitrectomy in diabetic eyes pretreated with bevacizumab (Avastin). Retina 29:926–931

    Article  PubMed  Google Scholar 

  30. Kompella UB, Bandi N, Ayalasomayajula SP (2003) Subconjunctival nano- and microparticles sustain retinal delivery of budesonide, a corticosteroid capable of inhibiting VEGF expression. Invest Ophthalmol Vis Sci 44:1192–1201

    Article  PubMed  Google Scholar 

  31. Nauck M, Roth M, Tamm M, Eickelberg O, Wieland H, Stulz P, Perruchoud AP (1997) Induction of vascular endothelial growth factor by platelet-activating factor and platelet-derived growth factor is downregulated by corticosteroids. Am J Respir Cell Mol Biol 16:398–406

    CAS  PubMed  Google Scholar 

  32. Sawada O, Kawamura H, Kakinoki M, Sawada T, Ohji M (2007) Vascular endothelial growth factor in aqueous humor before and after intravitreal injection of bevacizumab in eyes with diabetic retinopathy. Arch Ophthalmol 125:1363–1366

    Article  CAS  PubMed  Google Scholar 

  33. Romano MR, Gibran SK, Marticorena J, Wong D, Heimann H (2008) Can a preoperative bevacizumab injection prevent recurrent postvitrectomy diabetic vitreous haemorrhage? Eye

  34. Warner TD (1999) Relationships between the endothelin and nitric oxide pathways. Clin Exp Pharmacol Physiol 26:247–252

    Article  CAS  PubMed  Google Scholar 

  35. Romano MR, Gibran SK, Marticorena J, Wong D, Heimann H (2009) Can an intraoperative bevacizumab injection prevent recurrent postvitrectomy diabetic vitreous hemorrhage? Eur J Ophthalmol 19:618–621

    PubMed  Google Scholar 

  36. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RJ (2007) Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 114:855–859

    Article  PubMed  Google Scholar 

  37. Beer PM, Bakri SJ, Singh RJ, Liu W, Peters GB 3rd, Miller M (2003) Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. Ophthalmology 110:681–686

    Article  PubMed  Google Scholar 

  38. Chin HS, Park TS, Moon YS, Oh JH (2005) Difference in clearance of intravitreal triamcinolone acetonide between vitrectomized and nonvitrectomized eyes. Retina 25:556–560

    Article  PubMed  Google Scholar 

  39. Summanen P (1988) Neovascular glaucoma following vitrectomy for diabetic eye disease. Acta Ophthalmol (Copenh) 66:110–116

    Article  CAS  Google Scholar 

  40. Machemer R, Blankenship G (1981) Vitrectomy for proliferative diabetic retinopathy associated with vitreous hemorrhage. Ophthalmology 88:643–646

    CAS  PubMed  Google Scholar 

  41. Jonas JB, Hayler JK, Sofker A, Panda-Jonas S (2001) Regression of neovascular iris vessels by intravitreal injection of crystalline cortisone. J Glaucoma 10:284–287

    Article  CAS  PubMed  Google Scholar 

  42. Jonas JB, Hayler JK, Sofker A, Panda-Jonas S (2001) Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative diabetic retinopathy. Am J Ophthalmol 131:468–471

    Article  CAS  PubMed  Google Scholar 

  43. Gillies MC, Kuzniarz M, Craig J, Ball M, Luo W, Simpson JM (2005) Intravitreal triamcinolone-induced elevated intraocular pressure is associated with the development of posterior subcapsular cataract. Ophthalmology 112:139–143

    Article  PubMed  Google Scholar 

  44. Jonas JB, Degenring RF, Kreissig I, Akkoyun I, Kamppeter BA (2005) Intraocular pressure elevation after intravitreal triamcinolone acetonide injection. Ophthalmology 112:593–598

    Article  PubMed  Google Scholar 

  45. Smithen LM, Ober MD, Maranan L, Spaide RF (2004) Intravitreal triamcinolone acetonide and intraocular pressure. Am J Ophthalmol 138:740–743

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Ophthalmology, School of Medicine, Kyungpook National University, #50 Samduk-dong-2-ga, Chung-gu, Taegu, 700-721, South Korea

    Dong Ho Park, Jae Pil Shin & Si Yeol Kim

Authors
  1. Dong Ho Park
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jae Pil Shin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Si Yeol Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Si Yeol Kim.

Additional information

The authors have no financial interest in any materials or equipment used in the study. The authors have full control of all primary data and they agree to allow Graefe’s Archive for Clinical and Experimental Ophthalmology to review their data upon request.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Park, D.H., Shin, J.P. & Kim, S.Y. Intravitreal injection of bevacizumab and triamcinolone acetonide at the end of vitrectomy for diabetic vitreous hemorrhage: a comparative study. Graefes Arch Clin Exp Ophthalmol 248, 641–650 (2010). https://doi.org/10.1007/s00417-009-1247-7

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00417-009-1247-7

Keywords

Search

Navigation